Evidence map›Paper›PMID 40143091›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Mapping the Evolution of IBD Treatment: A Bibliometric Study on Biologics and Small Molecules.

Huibo Li, Jia Wang, Yang Hu, Wei Hu, Jun Li, Yang Liu, Rongsheng Zhao, Yi Zhun Zhu

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Response to Letter to the Editor.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huibo LiSchool of Pharmacy, Faculty of Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.ORCID 0000-0001-6807-8099
Jia WangDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Yang HuDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Wei HuSchool of Pharmacy, Faculty of Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Jun LiDepartment of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
Yang LiuSchool of Pharmacy, Faculty of Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Rongsheng ZhaoSchool of Pharmacy, Faculty of Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Yi Zhun ZhuSchool of Pharmacy, Faculty of Medicine & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.ORCID 0000-0001-7700-8041

Funding

Macau Science and Technology Development Fund FDCT (0012/2021/AMJ, 0001/2024/RDP, 0001/2024/AKP, 0092/2022/A2, 0144/2022/A3Peking University BMU2024YFJHPY040Peking University Third Hospital BYSYLXHG2024010Peking University Third Hospital BYSYZD2022022Shenzhen - Hong Kong - Macao Science and Technology Fund Category C: SGDX20220530111203020
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bibliometric studybiological productinflammatory bowel diseasesmall molecules

Identifiers

PMID40143091
PMCPMC11944940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.